Association Between the Interferon-γ +874 T/A Polymorphism and the Risk and Clinical Manifestations of Systemic Lupus Erythematosus: A Preliminary Study
Shanshan Liu,Ju Li,Yongsheng Li,Yan Liu,Kai Wang,Wenyou Pan
DOI: https://doi.org/10.2147/PGPM.S323491
2021-11-20
Pharmacogenomics and Personalized Medicine
Abstract:Shanshan Liu, Ju Li, Yongsheng Li, Yan Liu, Kai Wang, Wenyou Pan Department of Rheumatology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, People's Republic of China Correspondence: Shanshan Liu Department of Rheumatology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, People's Republic of China Email Background: Interferon-gamma (IFN-γ) is a pivotal cytokine involved in the development of systemic lupus erythematosus (SLE). The IFN-γ +874 T/A polymorphism has been shown to be related to the susceptibility to SLE in other races, but this has not been investigated in the Chinese Han population. Methods: We designed this study to interpret the potential correlation between this polymorphism and SLE risk in a Chinese Han population. We included 374 SLE patients and 405 controls in this study. Odds ratios and relevant 95% confidence intervals were figured out to evaluate the potential strength of the association. Results: Data revealed that the IFN-γ +874 T/A polymorphism showed an association with an enhanced risk of SLE in this Chinese Han population. TA or TA +AA genotype carriers showed an increased risk of developing SLE. Subgroup analyses found that this polymorphism elevated the risk of SLE among females. Additionally, this polymorphism was associated with clinical manifestations of SLE including lupus nephritis, proteinuria, anti-dsDNA antibodies, anti-Sm antibodies, and SLICC/ACR damage index. Furthermore, we conducted a meta-analysis and found that this polymorphism was associated with the risk of SLE, especially among Asians. Conclusion: Totally, this study detects that the IFN-γ +874 T/A polymorphism is related to the risk and clinical manifestations of SLE in a Chinese Han population. Keywords: interferon-gamma, systemic lupus erythematosus, case–control study, +874 T/A polymorphism Systemic lupus erythematosus (SLE), a chronic autoimmune disorder, is characterized by abnormalities of the immune system, autoantibodies production, multiple types of tissue damage, and other clinical symptoms. 1 Immune characteristics of SLE include loss of immunological self-tolerance, and enhanced T and B cell responses. 2 The prevalence of SLE ranges from 20 to 150 cases per 100,000 individuals, and appears to be increasing. 3 The pathogenesis of this disorder has not yet been fully elucidated. Numerous studies have demonstrated that genetic and environmental factors, and immune abnormalities are associated with the pathogenesis of SLE, 4–8 and have uncovered multiple loci related to SLE risk. 9–13 Interferon-gamma (IFN-γ) is a pivotal cytokine, which correlated with the development of autoimmune diseases. 14 IFN-γ is primarily produced by immune cells such as T and NK cells. IFN-γ is involved in both acquired and innate immunity, 15 and regulates immune responses such as antigen presentation and phagocytosis. The IFN-γ signaling pathway is activated in SLE patients. 16 Thomason et al showed that IFN-γ activation could indicate the disease activity of SLE patients. 17 In addition, the response to ustekinumab treatment in SLE patients was related to the suppression of serum IFN-γ levels. 18 Furthermore, IFN-γ was reported to be related to the cerebral atrophy in SLE patients. 19 Kokic et al demonstrated that the median values of IFN-γ were significantly elevated in patients with SLE than those in controls. 20 The IFN-γ gene is shown to be located on chromosome 12q24. A single-nucleotide polymorphism (SNP) was located at position +874 in the first intron of the IFN-γ gene, which was related to its production level. 21 Several studies have explored the potential link between the +874 T/A polymorphism in IFN-γ gene and SLE risk. 22–28 However, no Chinese studies have been undertaken to address this issue. In this case–control study, we aimed to interpret the relationship between this polymorphism and SLE risk and disease features in a Chinese Han population. In addition, we performed a meta-analysis to interpret the potential correlation between this locus and SLE risk. This study included 374 SLE cases and 405 controls from Huaian No.1 People's Hospital. SLE patients were diagnosed according to the 1997 American College of Rheumatology (ACR) criteria. 29 The average age of SLE patients was 34.42 ± 9.01 years. The inclusion criteria for SLE patients were patients receiving first treatment, and patients who met the revised SLE classification criteria of the ACR. Patients were excluded as follows: (1) subjects with autoimmune diseases; (2) patients had a family history of SLE; (3) patients received treatme -Abstract Truncated-
pharmacology & pharmacy